87 Participants Needed

NanO2 for Glioblastoma

(RESTORE Trial)

Recruiting at 11 trial locations
OL
EU
RW
Overseen ByRong Wang, MBA
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: NuvOx LLC
Must be taking: Temozolomide
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 2 JurisdictionsThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but it does exclude those on certain anticoagulant or antiplatelet therapies, except for specific medications like low-dose aspirin and some others. It's best to discuss your current medications with the trial team.

What data supports the effectiveness of the treatment NanO2 for glioblastoma?

Research on similar treatments, like perfluorocarbon nanoparticles, shows they can be effectively delivered to tumors and enhance imaging and drug delivery, as seen in lung cancer studies. Additionally, perfluorocarbon nanoemulsions have been shown to improve tumor ablation in other cancer treatments, suggesting potential benefits for glioblastoma.12345

Is NanO2 safe for use in humans?

Research on perfluorocarbon nanoparticles, similar to NanO2, shows they have been used safely in various medical applications, including improving lung function in infants and enhancing cancer treatments, without causing significant side effects. Studies indicate that these nanoparticles do not impact behavior or cause harmful changes in blood tests when administered in animals.12678

What makes the drug NanO2 unique for treating glioblastoma?

NanO2, also known as Dodecafluoropentane, is unique because it is a perfluorocarbon (a type of chemical compound) that can enhance oxygen delivery to tissues, potentially improving the effectiveness of treatments like radiation therapy for glioblastoma, a type of brain cancer. Unlike traditional treatments, it may offer a novel mechanism by increasing oxygen levels in tumor tissues, which can make cancer cells more susceptible to treatment.19101112

What is the purpose of this trial?

This trial is testing a new treatment that delivers more oxygen to tumors. It aims to help patients with a specific type of brain cancer by making radiation therapy more effective. By increasing oxygen levels in the tumor, the treatment helps radiation work better at killing cancer cells.

Eligibility Criteria

Adults with newly diagnosed glioblastoma who can have MRI scans, have a life expectancy of at least 3 months, and are in good enough health to undergo radiation and chemotherapy. They must not be pregnant or breastfeeding, agree to use effective birth control, and cannot have had any prior treatment for glioblastoma or other significant medical conditions that could interfere with the trial.

Inclusion Criteria

Ability to understand and the willingness to sign a written informed consent document.
I agree to use effective birth control during and for 4 months after the study.
I had an MRI within the last week without increasing my steroid dose.
See 14 more

Exclusion Criteria

I do not have any serious bleeding in my brain.
I know I do not have HIV or hepatitis B/C.
My cancer has spread to the lining of my brain and cannot be safely targeted with radiation.
See 17 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Radiation

Participants receive radiation therapy 5 days a week for 6 weeks, with either NanO2 or placebo infusions administered prior to radiation

6 weeks
5 visits per week (in-person)

Recovery

Participants undergo a recovery period following radiation therapy

4 weeks

Maintenance Chemotherapy

Participants receive six cycles of maintenance Temozolomide therapy on days 1 to 5 of each 28-day cycle

6 cycles of 28 days each

Follow-up

Participants are monitored for safety and effectiveness after treatment

5 years
Every 3 months for 3 years, then every 6 months for 2 years

Treatment Details

Interventions

  • NanO2TM
Trial Overview The trial is testing NanO2TM combined with standard radiation therapy and temozolomide chemotherapy. NanO2TM is designed to increase oxygen delivery to tumors which may enhance the effectiveness of radiation therapy against brain cancer.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: NanO2TMExperimental Treatment1 Intervention
NanO2TM infusion in conjunction with Radiation Treatment and temozolomide
Group II: PlaceboPlacebo Group1 Intervention
Placebo Saline infusion in conjunction with Radiation Treatment and temozolomide

NanO2TM is already approved in United States, Canada for the following indications:

๐Ÿ‡บ๐Ÿ‡ธ
Approved in United States as NanO2 for:
  • None approved; Orphan Drug Designation for glioblastoma and sickle cell anemia
๐Ÿ‡จ๐Ÿ‡ฆ
Approved in Canada as NanO2 for:
  • None approved; allowance for Phase Ib/II study in COVID-19 patients with respiratory distress

Find a Clinic Near You

Who Is Running the Clinical Trial?

NuvOx LLC

Lead Sponsor

Trials
7
Recruited
610+

Findings from Research

Intratracheal (IT) administration of perfluorocarbon (PFC) nanoparticles resulted in significant accumulation within lung tumors, demonstrating a localized delivery method that maintains high concentrations of the treatment directly at the tumor site for over 72 hours.
The study found that IT delivery of PFC nanoparticles did not adversely affect rabbit behavior or respiratory function, indicating a safe profile for this method of drug delivery in lung cancer treatment.
Local Intratracheal Delivery of Perfluorocarbon Nanoparticles to Lung Cancer Demonstrated with Magnetic Resonance Multimodal Imaging.Wu, L., Wen, X., Wang, X., et al.[2018]
The HMC-FMX nanoparticle platform enables effective visualization of glioblastoma multiforme (GBM) tumors during surgery by crossing the blood-brain barrier and selectively accumulating in the tumor, which is crucial for complete tumor resection.
This platform not only aids in tumor visualization but also facilitates the delivery of chemotherapeutic drugs like paclitaxel and cisplatin directly into GBM tumors, leading to reduced tumor size and improved survival rates in mouse models.
Near Infrared Fluorescent Nanoplatform for Targeted Intraoperative Resection and Chemotherapeutic Treatment of Glioblastoma.Reichel, D., Sagong, B., Teh, J., et al.[2023]
Using fluorine-19 MRI, researchers tracked the accumulation of perfluorocarbon nanoemulsions (PFCNEs) in tumors, finding that a concentration of 2-3 mg/mL significantly improved the effectiveness of high intensity focused ultrasound (HIFU) treatments.
The study demonstrated that the amount of PFCNE delivered directly influences the extent of tumor ablation, with histological analysis revealing varying levels of tissue necrosis based on PFCNE concentration, highlighting the potential of 19F MRI for optimizing tumor treatment.
Tracking Perfluorocarbon Nanoemulsion Delivery by 19F MRI for Precise High Intensity Focused Ultrasound Tumor Ablation.Shin, SH., Park, EJ., Min, C., et al.[2018]

References

Local Intratracheal Delivery of Perfluorocarbon Nanoparticles to Lung Cancer Demonstrated with Magnetic Resonance Multimodal Imaging. [2018]
Near Infrared Fluorescent Nanoplatform for Targeted Intraoperative Resection and Chemotherapeutic Treatment of Glioblastoma. [2023]
Tracking Perfluorocarbon Nanoemulsion Delivery by 19F MRI for Precise High Intensity Focused Ultrasound Tumor Ablation. [2018]
[Chemotherapeutic wafers in treatment of malignant cerebral glioma. Assessment of a Cochrane review]. [2013]
Neuronavigation-guided focused ultrasound (NaviFUS) for transcranial blood-brain barrier opening in recurrent glioblastoma patients: clinical trial protocol. [2022]
Perfluorocarbon nanodroplets stabilized with cisplatin-prodrug-constructed lipids enable efficient tumor oxygenation and chemo-radiotherapy of cancer. [2021]
Therapeutic oxygen delivery by perfluorocarbon-based colloids. [2021]
In vivo tracking of human neural stem cells with 19F magnetic resonance imaging. [2021]
5-Aminolevulinic Acid-Protoporphyrin IX Fluorescence-Guided Surgery of High-Grade Gliomas: A Systematic Review. [2018]
10.United Statespubmed.ncbi.nlm.nih.gov
Single-cell analysis of 5-aminolevulinic acid intraoperative labeling specificity for glioblastoma. [2023]
11.United Statespubmed.ncbi.nlm.nih.gov
In vitro labeling of glioma cells with gadofluorine M enhances T1 visibility without affecting glioma cell growth or motility. [2021]
[Glioblastoma, innovations in surgery]. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity